Sentinel lymph node biopsy in breast cancer.

Area of Science:

• Oncology
• Surgical Pathology
• Medical Imaging

Background:

• Sentinel lymph node (SLN) biopsy is emerging as a standard of care for breast cancer.
• Accurate staging is crucial for effective breast cancer treatment and management.

Purpose of the Study:

• To review the technique, case selection, and pathological analysis of SLN biopsy in breast cancer.
• To discuss the accuracy, identification rates, and implications of micrometastases in SLN biopsy.
• To assess the impact of SLN biopsy on regional disease control and patient survival.

Main Methods:

• Review of current literature on SLN biopsy techniques, including radioguided and blue dye lymphatic mapping.
• Discussion of tracer injection methods (intradermal, peri-tumoural, intra-tumoural) and their effect on drainage patterns.
• Analysis of data from ongoing and completed phase III trials (NSABP, BASO, ACOSOG, EORTC) evaluating SLN biopsy outcomes.

Main Results:

• High identification rates for SLN biopsy are achievable with both radioguided and blue dye lymphatic mapping.
• Intradermal tracer injection suggests dermal and parenchymal lymphatics share the same SLN, while extra-axillary drainage occurs with peri- or intra-tumoural injection.
• SLN biopsy accuracy is high in experienced hands; ongoing trials will determine its impact on survival and local control.

Conclusions:

• SLN biopsy is a rapidly evolving technique for breast cancer staging with high potential for accurate nodal assessment.
• Further research and large-scale trials are essential to fully understand the implications of micrometastases and the role of SLN biopsy in overall survival.
• The safety and efficacy of SLN biopsy depend on meticulous technique and experienced surgical teams.